Generics Need Sword, Shield For 'Exceptional' Patent Case

Strategies for generic drug companies to avoid paying exceptional-case attorney fees and costs in patent litigation with brand holder.

September 18, 2014

Generic drug companies marketing in the U.S. have particularly rough going these days. The year 2013 saw substantial new Generic Drug User Fee Amendments "user fees" levied on generics for access to the U.S.Food and Drug Administration. The same year brought the U.S. Supreme Court’s Actavis decision: Now the Federal Trade Commission can sue generics for structuring pharma litigation settlements such that the generic company receives something of value from the brand.

All Content © 2003‐2014, Portfolio Media, Inc.

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.


Related Publications

Second Quarter
ANDA Litigation Settlements
GENERICally Speaking Summer 2021
Second Quarter
New ANDA Cases
GENERICally Speaking Spring 2021
Second Quarter
ANDA Approvals
GENERICally Speaking Summer 2021
Second Quarter
Generic Launches
GENERICally Speaking Summer 2021
July 15, 2021
Biotechnology & Trade Secret Protection
Sharon Roberg-Perez, David Prange, Ellen Levish - Bloomberg Law
Back to Top